FerroKin BioSciences is focused on the development of medicines used to manage iron for the treatment of disease. We are currently conducting worldwide clinical trials to evaluate the safety, tolerability, and iron clearing activity of FBS0701, a once daily iron-binding compound, for the treatment of transfusional iron overload.
About FerroKin BioSciences
We are working to develop a medicine that will improve the lives of patients with iron overload. Our iron-binding compound, FBS0701, is currently being evaluated in a comprehensive clinical development program.
About Iron Overload
Transfusional iron overload results from chronic transfusions of red blood cells. These transfusions are needed to treat certain hereditary and acquired anemias. Approximately 200 million patients worldwide suffer from anemias that require transfusions.